ORIGINAL ARTICLE

HOMOCYSTEINE LEVELS IN CHRONIC KIDNEY DISEASE STAGE V / END STAGE RENAL DISEASE ON MAINTENANCE HEMODIALYSIS AND THEIR PROGNOSTIC VALUE INVASCULAR DISEASES
P. S. Usha Rani¹, S. M. Saifullah Quraishi², M. Manikanta³, P. Sudhakar⁴

HOW TO CITE THIS ARTICLE:
P. S. Usha Rani, S. M. Saifullah Quraishi, M. Manikanta, P. Sudhakar. "Homocysteine Levels in Chronic Kidney Disease Stage V / End Stage Renal Disease on Maintenance Hemodialysis and Their Prognostic Value In Vascular Diseases". Journal of Evidence based Medicine and Healthcare; Volume 2, Issue 43, October 26, 2015; Page: 7621-7632, DOI: 10.18410/jebmh/2015/1031

ABSTRACT: INTRODUCTION: Majority of patients with CKD stage V on maintenance hemodialysis have hyper homocysteinemia because of decreased excretion and loss of renal homocysteine metabolism. Homocysteine is a risk factor for vascular diseases. AIMS AND OBJECTIVES OF THE STUDY: To demonstrate hyper homocysteinemia in chronic kidney disease stage V on maintenance hemodialysis and to follow up these patients if they develop any vascular complications. MATERIALS AND METHODS: This study includes 30 patients with CKD stage V on maintenance hemodialysis with age variation between 35-72 years, and in these patients fasting plasma homocysteine levels was assayed. These patients were followed up for 2 years for vascular complications. CONCLUSION: Out of 30 patients of CKD stage V on maintenance hemodialysis, 25 patients (83.33%) have elevated homocysteine Levels. Majority of these patients, homocysteine levels are within moderate range (30-100µmol/l). On follow up no patient developed any major vascular complications such as symptomatic IHD, neurological deficits or any symptomatic peripheral vascular diseases.

KEYWORDS: Homocysteine, Hemodialysis, CKD, Cerebrovascular diseases, Cardiovascular diseases.

INTRODUCTION: Homocysteine is a sulphur containing amino acid which is produced during metabolism of the essential amino acid methionine.

Impaired kidney function leads to increased plasma homocysteine levels by 2 to 3 folds by following mechanisms:
1. Decreased excretion.
2. Decreased re methylation of homocysteine to methionine in tubule interstitium of kidney.[¹]

Direct correlation exists between increasing creatinine and homocysteine levels.[²] Hyper homocysteinemia is more prevalent in the hemodialysis patient than continuous ambulatory peritoneal dialysis, probably because of removal of water soluble vitamins such as B6, B12 during dialysis.[³] Thus majority of end stage renal disease patients on hemodialysis are burdened by additional cardio vascular risk factors of hyper homocysteinemia.[⁴,⁵] Thus hyper homocysteinemia in chronic kidney disease is mainly because of decreased excretion and loss of renal homocysteine metabolism which normally accounts for 70% of daily elimination of homocysteine from plasma.
High homocysteine levels are associated with vascular disease.\(^6\) Such as;
- Atherosclerosis.\(^7\)
- Cardiovascular diseases:\(^8\)
- Cerebrovascular diseases.\(^9,10\)

**AIMS AND OBJECTIVES OF THE STUDY:** To demonstrate hyper homocysteinemia in chronic kidney disease stage V on maintenance hemodialysis and to follow up these patients if they develop any vascular complications.

**MATERIALS AND METHODS:** Adult patient with chronic kidney disease stage V on maintenance hemodialysis presenting to the department of nephrology at Govt. General Hospital, Kurnool.

**Study Type:** Cross-sectioned study with follow up for 2 years for vascular complications.

**Sample Size:** 30.

Investigations done in my study;
1. Homocysteine levels estimation by FLUORESCENCE POLARIZATION IMMUNOASSAY.
2. Complete blood picture.
3. Blood urea.
4. Serum Creatinine.
5. Blood Sugar.
6. Lipid profile.
7. Thyroid function test.
8. Serum electrolytes.
9. Serum calcium, phosphorus, alkaline phosphates.
10. ECG.
11. Ultra sound abdomen.
12. Urine for albumin, sugar and deposits.
13. CT-Brain.
14. 2D Echo.
15. Doppler study of neck vessel.
16. Doppler study of lower limb vessel.

**Inclusion Criteria:** All patients with chronic kidney diseases stage V/ end stage renal disease on maintenance hemodialysis.

**Exclusion Criteria:**
1. Patients having previous history of IHD, CVD, PVD.
2. Patients not having any malignancies.
3. Patient on medications such as metformin, Methotrexate, Niacin, anticonvulsants.
RESULTS:

| Patient age group | No. of Males | No. of Females | Total No. of Patients | Percentage |
|-------------------|--------------|----------------|-----------------------|------------|
| 31-40             | 4            | 4              | 8                     | 26         |
| 41-50             | 19           | 6              | 15                    | 50         |
| 51-60             | 5            | 0              | 5                     | 16.5       |
| 61-70             | 1            | 0              | 1                     | 3.33       |
| 71-80             | 1            | 0              | 1                     | 3.33       |

Table 1: Age distribution of cases

Mean=51. Out of 30 patients 50% of the patient’s age is within 41-50 years.

Male: Female ratio=2:1.

| Sex       | No. of patients | Percentage |
|-----------|-----------------|------------|
| Males     | 20              | 66.66      |
| Females   | 10              | 33.33      |

Table 2: Sex distribution of cases

| Grading of Homocysteine levels | No. of Male Patients | Percentage of Male Patients |
|--------------------------------|----------------------|----------------------------|
| Normal <15µmol/L               | 4                    | 20                         |
| Moderate 15-30µmol/L          | 5                    | 25                         |
| Intermediate 30-100µmol/L     | 8                    | 40                         |
| Severe >100µmol/L             | 3                    | 15                         |

Table 3: Grading of Homocysteine levels in Male patients & their percentages
Majority (40%) of male patients with homocysteine levels are within intermediate range.

| Grading of Homocysteine levels | No. of Female Patients | Percentage of Female Patients |
|-------------------------------|------------------------|-----------------------------|
| Normal <15µmol/L              | 1                      | 10                          |
| Moderate 15-30µmol/L          | 5                      | 50                          |
| Intermediate 30-100 µmol/L    | 4                      | 40                          |
| Severe >100µmol/L             | 0                      | 0                           |

Table 4: Grading of Homocysteine levels in female patients & their percentages

Majority (50%) of female patients with homocysteine levels are within moderate range.

| Hey levels of CKD stage V patients on MHD total No. of pt-30 | Grading of Hyper homocysteinemia | Total no. of patients | Percentage |
|-------------------------------------------------------------|---------------------------------|-----------------------|------------|
| <15µmol/L                                                   | Normal                          | 5                     | 16.66      |
| 15-30µmol/L                                                 | Moderate                        | 10                    | 33.33      |
| 30-100 µmol/L                                               | Intermediate                    | 12                    | 40         |
| >100µmol/L                                                  | Severe                          | 3                     | 10         |

Table 5: Grading of Homocysteine levels in total sample size & their percentages

- Percentage of patients with normal homocysteine levels-16.66%.
- Percentage of patients with hyperhomocystenemia-83.33%.
- Out of this majority (12 in number) of patients of patient Homocysteine levels are within intermediate range.
Homocysteine levels of CKD stage V patients on MHD

| Homocysteine levels | Grading of Hyper homocysteinemia | Total no. of patients | No. of patients developing symptomatic IHD | No. of patients having RWMA as evidenced by 2D-Echo |
|---------------------|----------------------------------|-----------------------|-----------------------------------------|-------------------------------------------------|
| <15µmol/L           | Normal                           | 5                     | 0                                       | 1                                               |
| 15-30µmol/L         | Moderate                         | 10                    | 0                                       | 1                                               |
| 30-100 µmol/L       | Intermediate                     | 12                    | 0                                       |                                                 |
| >100µmol/L          | Severe                           | 3                     | 0                                       | 1                                               |

Table 6: CVS changes in CKD patients according to grading of Homocysteine

Graph 6

No. of patients developed symptomatic IHD and 2D echo evidence of RWMA in moderate, intermediate severe hyper Homocysteinemia.

- Percentage of patients developed symptomatic IHD-nil.
- Percentage of patients with normal Hey level developed RWMA-20%.
- Percentage of patients with hyper Homocysteinemia developed RWMA-20%.
- No significant difference made out between normal or hyper Homocysteinemia patients.

Homocysteine levels of CKD stage V patients on MHD

| Homocysteine levels | Grading of Hyper Homocysteinemia | Total no. of Patients | No. of patients developing neurological deficit | No. of patients Developed lacunar infarcts in CT brain S/O small vessel stroke |
|---------------------|----------------------------------|-----------------------|------------------------------------------------|--------------------------------------------------------------------------------|
| <15µmol/L           | Normal                           | 5                     | 0                                               | 1                                                                            |
| 15-30µmol/L         | Moderate                         | 10                    | 0                                               | 2                                                                            |
| 30-100 µmol/L       | Intermediate                     | 12                    | 0                                               | 3                                                                            |
| >100µmol/L          | Severe                           | 3                     | 0                                               | 1                                                                            |

Table 7: CNS changes in CKD patients according to grading of Homocysteine
No. of patients developed neurological deficit and lacunar infarcts in CT brain S/O small vessel stroke in normal and moderate, intermediate severe hyper Homocysteinemia.

- Percentage of patients developed neurological deficit – nil.
- Percentage of patients with normal Homocysteine level developed lacunar infarcts - 20%.
- Percentage of patients with hyper Homocysteinemia developed lacunar infarcts - 24%.
- No significant difference made out between normal or hyper Homocysteinemia patients.

| Homocysteine levels of CKD stage V patients on MHD | Grading of Hyper Homocysteinemia | Total no. of Patients | No. of Peripheral Vascular diseases |
|---------------------------------------------------|---------------------------------|-----------------------|-----------------------------------|
| <15µmol/L                                         | Normal                          | 5                     | 0                                 |
| 15-30µmol/L                                       | Moderate                        | 10                    | 0                                 |
| 30-100 µmol/L                                     | Intermediate                    | 12                    | 0                                 |
| >100µmol/L                                        | Severe                          | 3                     | 0                                 |

Table 8: Peripheral vascular diseases in CKD patients according to grading of Homocysteine
No. of patients developing peripheral vascular diseases in patients with moderate, intermediate severe hyper Homocysteinemia.

Percent of patients developing peripheral vascular disease – nil.

| Homocysteine levels of CKD stage V patients on MHD | Grading of Hyper Homocysteinemia | Total no. of patients | No. of Patients Developed abnormalities in Doppler study of neck vessels |
|----------------------------------------------------|---------------------------------|-----------------------|---------------------------------------------------|
| <15µmol/L                                          | Normal                          | 5                     | 1                                                 |
| 15-30µmol/L                                        | Moderate                        | 10                    | 2                                                 |
| 30-100 µmol/L                                      | Intermediate                    | 12                    | 2                                                 |
| >100µmol/L                                         | Severe                          | 3                     | 1                                                 |

Table 9: Abnormalities in Doppler study in CKD patients according to grading of Homocysteine
No. of patients developed abnormalities in Doppler study of neck vessels normal and moderate, intermediate severe hyper Homocysteinemia.

- Percentage of patients with normal Homocysteine level developed abnormalities in Doppler study of neck vessels -20%.
- Percentage of patients with hyper Homocysteinemia developed abnormalities in Doppler study of neck vessels -20%.
- No significant difference made out between normal or hyper Homocysteinemia patients.

| Patients Homocysteine value | No. of patients with abnormal Echo findings present | No. of patients with abnormal Echo findings absent | Total no. of patients |
|-----------------------------|---------------------------------------------------|--------------------------------------------------|-----------------------|
| Normal <15µmol/L           | 1                                                 | 4                                                | 5                     |
| Elevated >15-30µmol/L      | 5                                                 | 20                                               | 25                    |
| Total                       | 6                                                 | 24                                               | 30                    |

Table 10: Echo findings in patients with normal & hyper Homocysteinemia

Yates corrected $X^2$: 0.37.  
df=1.  
2 tailed P=0.54: NS (Non-Significant).

| Patients Homocysteine value | No. of patients with abnormal CT findings present | No. of patients with abnormal CT findings absent | Total no. of Patients |
|-----------------------------|---------------------------------------------------|--------------------------------------------------|-----------------------|
| Normal <15µmol/L           | 1                                                 | 4                                                | 5                     |
| Elevated >15-30µmol/L      | 6                                                 | 19                                               | 25                    |
| Total                       | 7                                                 | 23                                               | 30                    |

Table 11: CT findings in patients with normal & hyper Homocysteinemia

Yates corrected $X^2$:0.14.  
df=1.  
2 tailed P=0.69: NS (Non-Significant).

| Patients Homocysteine value | No. of patients with abnormal carotid Doppler findings present | No. of patients with abnormal carotid Doppler findings absent | Total no. of patients |
|-----------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-----------------------|
| Normal <15µmol/L           | 1                                                             | 4                                                             | 5                     |
| Elevated >15-30µmol/L      | 5                                                             | 20                                                            | 25                    |
| Total                       | 6                                                             | 24                                                            | 30                    |

Table 12: Carotid Doppler findings in patients with normal & hyper Homocysteinemia
Yates corrected \( X^2 : 0.37 \).
df = 1.
2 tailed \( P = 0.54 \): NS (Non-Significant).

**DISCUSSION:** Fasting plasma Homocysteine levels were estimated in 30 patients of which 20 were males & 10 were females with CKD- Stage V on maintenance hemodialysis, age varying between 35-72 years. Majority (50%) of patient’s age within 41-50 years. These patients were followed up for 2 years for evaluation of any vascular complications.

According to plasma Homocysteine levels these patients were graded as;
1. Normal <15µmol/l.
2. Moderate 15-30µmol/l.
3. Intermediate 30-100 µmol/l.
4. Severe >100µmol/l.

Out of 30 patients 25 patients (83.33%) have elevated Homocysteine levels & majority of patients with Homocysteine values are in Intermediate range i.e. 30-100 µmol/l.

On follow up of these 30 patients no patient developed any major vascular complication such as symptomatic ischemic heart disease or neurological deficits or any symptomatic peripheral vascular disease. On observation there is no significant difference in occurrence of major vascular complications in hyper homocysteinemia when compared to normal homocysteinemia. And in the same follow up these patients have underwent some investigations, which show abnormalities like RWMA in 2D Echo, changes suggestive of ischemic in ECG, Lacunar infarcts in CT-Brain, mild atherosclerotic changes without any significant block in Doppler study of neck vessels.

From all the above observations finally the patients in the study were divided into 2 groups;
1. Normal homocysteine level patients (<15µmol/l) - 5 in no.
2. Hyper homocysteinemic patients (>15µmol/l) - 25 in no.

Among these two groups P value is calculated for 2 variables such as abnormal findings present or absent in 2D Echo, CT-Brain Doppler study of neck vessels which shows non-significance.

From the above discussion it is concluded that majority of patients with CKD stage V on maintenance hemodialysis have elevated homocysteine levels. 40% of these patients homocysteine values are within intermediate range i.e. 30-100 µmol/l. but these CKD patients with hyper homocysteinemia does not develop any major vascular complications except for minor morbidity when compared to normal homocysteine level patients.

References which shows non-significant relationship between homocysteine and vascular complications;
1. In a case–control study, conducted in Care Hospital, Hyderabad.\textsuperscript{[11]} Study concluded that there is no statistically significant difference in plasma homocysteine levels between controls and cases with coronary artery disease.

2. Another study conducted Madras Diabetic Research Foundation, Chennai.\textsuperscript{[12]} They concluded that elevated serum homocysteine levels are not associated with coronary artery.

3. The utility of homocysteine in predicting risk for atherothrombotic vascular disease has been evaluated in several observational studies in a large number of patients. These studies show that the overall risk for vascular disease is small, with prospective, longitudinal studies reporting a weaker association between homocysteine and atherothrombotic vascular disease compared to retrospective case-control and cross-sectional studies. Furthermore, randomized controlled trials of homocysteine-lowering therapy have failed to prove a causal relationship. On the basis of these results, there is currently insufficient evidence to recommend routine screening and treatment of elevated homocysteine concentrations with folic acid and other vitamins to prevent atherothrombotic vascular disease.\textsuperscript{[13]}

4. The study conducted in Department Nutrition National Public Health Institute, Helsinki, Finland.\textsuperscript{[14]} There was also no significant association between homocysteine and atherosclerotic disease, myocardial infarction or stroke in logistic regression analysis. The results of this prospective population based study do not support the hypotheses that serum homocysteine is a risk factors for atherosclerotic disease.

**CONCLUSION:** From the above discussion.

1. It is concluded that majority 83.33% of patients with CKD stage V on maintenance hemodialysis have elevated homocysteine levels. 40% of these patients homocysteine values are within intermediate range i.e. 30-100µmol/l.

2. But these CKD patients with hyper homocysteinemia did not develop any major vascular complications except for minor morbidity when compared to normal homocysteine level patients. The above study suggests a lack of association between hyper homocysteinemia and vascular disease in patients with CKD stage V on maintenance hemodialysis.

3. The results however must be interpreted with caution due to limitation of the study firstly, the sample size was very small secondly we did not adjust for other cardiovascular risk factors again due to small sample size thirdly the duration of study is small i.e. 2 years only. Hence larger studies with longer duration of follow up needs to be done for further confirmation.

**REFERENCES:**

1. Van Guldener, (2006): Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol Dial Transplant 21: 1161-1166.

2. Shankar A., Wang J.J., Chua B., rochtchina E., Flood V. and Mitchell P. (2008): Positive association between plasma homocysteine level and chronic kidney disease. Kidney Blood Press Res 31: 55-62.

3. Amadotteir M. The effect of reduced GFR on plasma total homocysteine concentration. Scand J Clin Lab Invest 19%; 56: 41-6.
4. Harker LA, Slichter SJ, Scott CR, et al. Homocysteinemia: Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-43.
5. Tawakol A, Omland T, Gerhand M, et al. Hyper homocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997; 95: 1119-21.
6. Mc Cully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-9.
7. Mc Cully KS. Vascular pathology of Homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-28.
8. Wald NJ, Watt HC et al. Homocysteine and ischemic heart disease: Result of a prospective study with implications on prevention. Arch Intern Med 1998; 158: 862-7.
9. Sainani G.S., Sainani R. Homocysteine and its role in the pathogenesis of atherosclerotic vascular disease. JAPI, 2002; 50 (suppl): 16-23.
10. Selhub J, Jacques PF et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995; 332: 286-91.
11. Sastry BK, Indira N, Anand B, Kedarnath, Praba BS, Raju BS, A case control study of plasma homocysteine levels in south Indians with and without coronary artery disease. Care Hospital, Nampally, Hyderabad, Indian Heart J. 2001 Nov-Dec; 56(6): 749-53.
12. Deepa.K, Velmurugan G Saravanan, K Kartkuzhaili, V Dwarakanath, V Mohan, Madras diabetes Research Foundation, Gopalapuram, Chennai, Dept. of Arthrohacl Surgery, Govt. General Hospital, Chennai. Absence of association Between Serum Homocysteine Levels and Coronary Artery Disease in South Indian Males. Indian Heart J 2001; 53: 54: 44-47.
13. CS Yajnik, Swapna S Deshpande, Himangi G Lubree, SS Naik, DS BhatBhagyashree, S Uradey, Jyoti, A Deshpande, Sonali, S Rege, Helga, Refsum, JS Yudkin JAPI, Vol; 54, Oct-2006. 775-781.
14. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomiletho J, Salonen JT, Ehnhcim C. Dept of Nutrition, National Public Health Institute, Helsinki, Finland. Relation of serum homocysteine to atherosclerotic disease in a prospective Finnish population based study.
## ORIGINAL ARTICLE

### AUTHORS:
1. P. S. Usha Rani
2. S. M. Saifullah Quraishi
3. M. Manikanta
4. P. Sudhakar

### PARTICULARS OF CONTRIBUTORS:
1. Assistant Professor, Department of General Medicine, Kurnool Medical College, Kurnool.
2. Assistant Professor, Department of General Medicine, Kurnool Medical College, Kurnool.
3. Post Graduate, Department of General Medicine, Kurnool Medical College, Kurnool.
4. Professor and HOD, Department of General Medicine, Kurnool Medical College, Kurnool.

### NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. S. M. Saifullah Quraishi,
50/761/3, Devanagar,
Kurnool-518001.
E-mail: sasu53@yahoo.co.in

Date of Submission: 04/09/2015.
Date of Peer Review: 05/09/2015.
Date of Acceptance: 14/10/2015.
Date of Publishing: 21/10/2015.